Download PDF
Semin Liver Dis 2015; 35(01): 012-025
DOI: 10.1055/s-0034-1397345
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

MicroRNAs in Fatty Liver Disease

Cyril Sobolewski
1   Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
Nicolas Calo
1   Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
Dorothea Portius
1   Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
Michelangelo Foti
1   Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
29 January 2015 (online)

    Permissions and Reprints

Abstract

Overweight and obesity, insulin resistance and diabetes, chronic alcoholism, as well as infection by specific genotypes of hepatitis C viruses are all associated with an excessive and chronic ectopic accumulation of fat in the liver (steatosis). If the underlining causes of steatosis development are not resolved, progression toward more severe liver diseases such as inflammation, fibrosis, and cirrhosis can then occur with time. These hepatic metabolic and histological disorders are commonly referred to as fatty liver disease (FLD) and result from multiple deregulated molecular mechanisms controlling hepatic homeostasis. Among these mechanisms, deregulation of a whole network of small noncoding RNAs called microRNAs (miRNAs), which regulate gene expression at a posttranscriptional level, critically contributes to the development and progression of FLD. Specific miRNAs secreted in body fluids are also emerging as useful biomarkers of FLD and therapeutic targeting of miRNAs is currently being evaluated. The authors discuss recent findings highlighting the role and complexity of miRNA regulatory networks, which critically contribute to the development of FLD. As well, the potential therapeutic perspectives for FLD that our understanding of hepatic miRNA biology offers is considered.

Keywords

steatosis - steatohepatitis - fibrosis - cirrhosis - noncoding RNA
 

  • References

  • 1 Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011; 8 (9) 491-501
    CrossrefPubMedGoogle Scholar
  • 2 Negro F. Hepatitis C virus-induced steatosis: an overview. Dig Dis 2010; 28 (1) 294-299
    CrossrefPubMedGoogle Scholar
  • 3 Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59 (2) 713-723
    CrossrefPubMedGoogle Scholar
  • 4 Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; 19 (29) 5169-5176
    CrossrefPubMedGoogle Scholar
  • 5 Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012; 30 (2) 158-162
    CrossrefPubMedGoogle Scholar
  • 6 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 (5) 1820-1832
    CrossrefPubMedGoogle Scholar
  • 7 Samuel VT, Liu ZX, Qu X , et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279 (31) 32345-32353
    CrossrefPubMedGoogle Scholar
  • 8 Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008; 7 (2) 95-96
    CrossrefPubMedGoogle Scholar
  • 9 Farese Jr RV, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 2012; 15 (5) 570-573
    CrossrefPubMedGoogle Scholar
  • 10 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383 (9930) 1749-1761
    CrossrefPubMedGoogle Scholar
  • 11 Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell 2013; 153 (3) 516-519
    CrossrefPubMedGoogle Scholar
  • 12 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116 (2) 281-297
    CrossrefPubMedGoogle Scholar
  • 13 Rayner KJ, Esau CC, Hussain FN , et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478 (7369) 404-407
    CrossrefPubMedGoogle Scholar
  • 14 Patrick DM, Montgomery RL, Qi X , et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010; 120 (11) 3912-3916
    CrossrefPubMedGoogle Scholar
  • 15 Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505 (7483) 344-352
    CrossrefPubMedGoogle Scholar
  • 16 Young LE, Moore AE, Sokol L, Meisner-Kober N, Dixon DA. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res 2012; 10 (1) 167-180
    CrossrefPubMedGoogle Scholar
  • 17 Horie T, Nishino T, Baba O , et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun 2013; 4: 2883
    PubMedGoogle Scholar
  • 18 Ng R, Wu H, Xiao H , et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 2014; 60 (2) 554-564
    PubMedGoogle Scholar
  • 19 Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10 (9) 542-552
    CrossrefPubMedGoogle Scholar
  • 20 Shibata C, Kishikawa T, Otsuka M , et al. Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression. Biochem Biophys Res Commun 2013; 438 (1) 230-235
    CrossrefPubMedGoogle Scholar
  • 21 Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 2010; 51 (6) 1513-1523
    CrossrefPubMedGoogle Scholar
  • 22 Esau C, Davis S, Murray SF , et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3 (2) 87-98
    CrossrefPubMedGoogle Scholar
  • 23 Nie YQ, Cao J, Zhou YJ , et al. The effect of miRNA-122 in regulating fat deposition in a cell line model. J Cell Biochem 2014; 115 (5) 839-846
    CrossrefPubMedGoogle Scholar
  • 24 Li S, Chen X, Zhang H , et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009; 50 (9) 1756-1765
    CrossrefPubMedGoogle Scholar
  • 25 Alisi A, Masotti A, Nobili V. Profiling microRNA expression: a snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis. Hepatology 2009; 49 (2) 706-707
    CrossrefPubMedGoogle Scholar
  • 26 Trebicka J, Anadol E, Elfimova N , et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58 (2) 234-239
    CrossrefPubMedGoogle Scholar
  • 27 Dippold RP, Vadigepalli R, Gonye GE, Patra B, Hoek JB. Chronic ethanol feeding alters miRNA expression dynamics during liver regeneration. Alcohol Clin Exp Res 2013; 37 (Suppl. 01) E59-E69
    CrossrefPubMedGoogle Scholar
  • 28 Tsai WC, Hsu SD, Hsu CS , et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122 (8) 2884-2897
    CrossrefPubMedGoogle Scholar
  • 29 Hsu SH, Wang B, Kota J , et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122 (8) 2871-2883
    CrossrefPubMedGoogle Scholar
  • 30 Bhatia H, Verma G, Datta M. miR-107 orchestrates ER stress induction and lipid accumulation by post-transcriptional regulation of fatty acid synthase in hepatocytes. Biochim Biophys Acta 2014; 1839 (4) 334-343
    CrossrefPubMedGoogle Scholar
  • 31 Xiao F, Yu J, Liu B , et al. A novel function of microRNA 130a-3p in hepatic insulin sensitivity and liver steatosis. Diabetes 2014; 63 (8) 2631-2642
    CrossrefPubMedGoogle Scholar
  • 32 Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci 2006; 63 (5) 524-539
    CrossrefPubMedGoogle Scholar
  • 33 Higuchi N, Kato M, Shundo Y , et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res 2008; 38 (11) 1122-1129
    CrossrefPubMedGoogle Scholar
  • 34 Zhong D, Zhang Y, Zeng YJ , et al. MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRα. Lipids Health Dis 2013; 12: 32
    CrossrefPubMedGoogle Scholar
  • 35 Zhong D, Huang G, Zhang Y , et al. MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes. Cell Signal 2013; 25 (6) 1429-1437
    CrossrefPubMedGoogle Scholar
  • 36 Adlakha YK, Khanna S, Singh R, Singh VP, Agrawal A, Saini N. Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis. Cell Death Dis 2013; 4: e780
    CrossrefPubMedGoogle Scholar
  • 37 Miller AM, Gilchrist DS, Nijjar J , et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE 2013; 8 (8) e72324
    CrossrefPubMedGoogle Scholar
  • 38 Shirasaki T, Honda M, Shimakami T , et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 2013; 87 (9) 5270-5286
    CrossrefPubMedGoogle Scholar
  • 39 Peyrou M, Ramadori P, Bourgoin L, Foti M. PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res 2012; 2012: 757803
    PubMedGoogle Scholar
  • 40 Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005; 288 (6) E1195-E1205
    CrossrefPubMedGoogle Scholar
  • 41 Li X. SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai) 2013; 45 (1) 51-60
    CrossrefPubMedGoogle Scholar
  • 42 Zhou B, Li C, Qi W , et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 2012; 55 (7) 2032-2043
    CrossrefPubMedGoogle Scholar
  • 43 Lee J, Padhye A, Sharma A , et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J Biol Chem 2010; 285 (17) 12604-12611
    CrossrefPubMedGoogle Scholar
  • 44 Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 2012; 287 (13) 9817-9826
    CrossrefPubMedGoogle Scholar
  • 45 Dávalos A, Goedeke L, Smibert P , et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011; 108 (22) 9232-9237
    CrossrefPubMedGoogle Scholar
  • 46 Zhang Y, Cheng X, Lu Z , et al. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res Clin Pract 2013; 99 (3) 327-334
    CrossrefPubMedGoogle Scholar
  • 47 Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 2013; 19 (3) 210-215
    CrossrefPubMedGoogle Scholar
  • 48 Ramirez CM, Dávalos A, Goedeke L , et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 2011; 31 (11) 2707-2714
    CrossrefPubMedGoogle Scholar
  • 49 Gerin I, Clerbaux LA, Haumont O , et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010; 285 (44) 33652-33661
    CrossrefPubMedGoogle Scholar
  • 50 Goedeke L, Vales-Lara FM, Fenstermaker M , et al. A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol Cell Biol 2013; 33 (11) 2339-2352
    CrossrefPubMedGoogle Scholar
  • 51 Allen RM, Marquart TJ, Albert CJ , et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med 2012; 4 (9) 882-895
    CrossrefPubMedGoogle Scholar
  • 52 Hoekstra M, van der Sluis RJ, Kuiper J, Van Berkel TJ. Nonalcoholic fatty liver disease is associated with an altered hepatocyte microRNA profile in LDL receptor knockout mice. J Nutr Biochem 2012; 23 (6) 622-628
    CrossrefPubMedGoogle Scholar
  • 53 Kang MH, Zhang LH, Wijesekara N , et al. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler Thromb Vasc Biol 2013; 33 (12) 2724-2732
    CrossrefPubMedGoogle Scholar
  • 54 Karagianni P, Talianidis I. Transcription factor networks regulating hepatic fatty acid metabolism. Biochim Biophys Acta 2014; ; (May): 9
    PubMedGoogle Scholar
  • 55 Singaravelu R, Chen R, Lyn RK , et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology 2014; 59 (1) 98-108
    CrossrefPubMedGoogle Scholar
  • 56 Kida K, Nakajima M, Mohri T , et al. PPARα is regulated by miR-21 and miR-27b in human liver. Pharm Res 2011; 28 (10) 2467-2476
    CrossrefPubMedGoogle Scholar
  • 57 Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009; 49 (4) 1176-1184
    CrossrefPubMedGoogle Scholar
  • 58 Zheng L, Lv GC, Sheng J, Yang YD. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol 2010; 25 (1) 156-163
    CrossrefPubMedGoogle Scholar
  • 59 Baroukh N, Ravier MA, Loder MK , et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 2007; 282 (27) 19575-19588
    CrossrefPubMedGoogle Scholar
  • 60 Ahn J, Lee H, Jung CH, Ha T. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res 2012; 56 (11) 1665-1674
    CrossrefPubMedGoogle Scholar
  • 61 Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F, Foti M. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 2008; 134 (1) 268-280
    CrossrefPubMedGoogle Scholar
  • 62 Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000; 20: 663-697
    CrossrefPubMedGoogle Scholar
  • 63 Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res 2004; 45 (5) 941-947
    CrossrefPubMedGoogle Scholar
  • 64 Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013; 19 (7) 892-900
    CrossrefPubMedGoogle Scholar
  • 65 González-Rodríguez A, Mayoral R, Agra N , et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis 2014; 5: e1179
    CrossrefPubMedGoogle Scholar
  • 66 Lin CW, Zhang H, Li M , et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol 2013; 58 (5) 993-999
    CrossrefPubMedGoogle Scholar
  • 67 Vescovo T, Romagnoli A, Perdomo AB , et al. Autophagy protects cells from HCV-induced defects in lipid metabolism. Gastroenterology 2012; 142 (3) 644-653.e3
    CrossrefPubMedGoogle Scholar
  • 68 Frankel LB, Lund AH. MicroRNA regulation of autophagy. Carcinogenesis 2012; 33 (11) 2018-2025
    CrossrefPubMedGoogle Scholar
  • 69 Seca H, Lima RT, Lopes-Rodrigues V, Guimaraes JE, Almeida GM, Vasconcelos MH. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets 2013; 14 (10) 1135-1143
    CrossrefPubMedGoogle Scholar
  • 70 Wang J, Yang K, Zhou L , et al. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog 2013; 9 (10) e1003697
    CrossrefPubMedGoogle Scholar
  • 71 Xu Y, An Y, Wang Y , et al. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2013; 29 (5) 2019-2024
    PubMedGoogle Scholar
  • 72 Meng F, Glaser SS, Francis H , et al. Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol 2012; 181 (3) 804-817
    CrossrefPubMedGoogle Scholar
  • 73 Yang J, Chen D, He Y , et al. MiR-34 modulates Caenorhabditis elegans lifespan via repressing the autophagy gene atg9. Age (Dordr) 2013; 35 (1) 11-22
    CrossrefPubMedGoogle Scholar
  • 74 Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab 2012; 16 (4) 414-419
    CrossrefPubMedGoogle Scholar
  • 75 Seo YK, Jeon TI, Chong HK, Biesinger J, Xie X, Osborne TF. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy. Cell Metab 2011; 13 (4) 367-375
    CrossrefPubMedGoogle Scholar
  • 76 Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148 (5) 852-871
    CrossrefPubMedGoogle Scholar
  • 77 Trajkovski M, Hausser J, Soutschek J , et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011; 474 (7353) 649-653
    CrossrefPubMedGoogle Scholar
  • 78 Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers Jr MG, Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 1998; 273 (41) 26962-26968
    CrossrefPubMedGoogle Scholar
  • 79 Wang Y, Hu C, Cheng J , et al. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem Biophys Res Commun 2014; 446 (4) 1255-1260
    CrossrefPubMedGoogle Scholar
  • 80 Wen F, Yang Y, Jin D, Sun J, Yu X, Yang Z. MiRNA-145 is involved in the development of resistin-induced insulin resistance in HepG2 cells. Biochem Biophys Res Commun 2014; 445 (2) 517-523
    CrossrefPubMedGoogle Scholar
  • 81 Ryu HS, Park SY, Ma D, Zhang J, Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE 2011; 6 (3) e17343
    CrossrefPubMedGoogle Scholar
  • 82 Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, Datta M. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol 2011; 332 (1–2) 125-133
    CrossrefPubMedGoogle Scholar
  • 83 Leslie NR, Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci 2011; 32 (3) 131-140
    CrossrefPubMedGoogle Scholar
  • 84 Jordan SD, Krüger M, Willmes DM , et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011; 13 (4) 434-446
    CrossrefPubMedGoogle Scholar
  • 85 Weber-Boyvat M, Zhong W, Yan D, Olkkonen VM. Oxysterol-binding proteins: functions in cell regulation beyond lipid metabolism. Biochem Pharmacol 2013; 86 (1) 89-95
    CrossrefPubMedGoogle Scholar
  • 86 Olivieri F, Rippo MR, Procopio AD, Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. Front Genet 2013; 4: 121
    PubMedGoogle Scholar
  • 87 McDaniel K, Herrera L, Zhou T , et al. The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med 2014; 18 (2) 197-207
    CrossrefPubMedGoogle Scholar
  • 88 Bala S, Marcos M, Kodys K , et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor alpha (TNFalpha) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011; 286 (2) 1436-1444
    CrossrefPubMedGoogle Scholar
  • 89 Jiang M, Broering R, Trippler M , et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Viral Hepat 2014; 21 (2) 99-110
    CrossrefPubMedGoogle Scholar
  • 90 Dolganiuc A, Petrasek J, Kodys K , et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 2009; 33 (10) 1704-1710
    CrossrefPubMedGoogle Scholar
  • 91 Sarma NJ, Tiriveedhi V, Crippin JS, Chapman WC, Mohanakumar T. Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. J Virol 2014; 88 (7) 3733-3743
    CrossrefPubMedGoogle Scholar
  • 92 Cheung O, Puri P, Eicken C , et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48 (6) 1810-1820
    CrossrefPubMedGoogle Scholar
  • 93 Wen J, Friedman JR. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 2012; 122 (8) 2773-2776
    CrossrefPubMedGoogle Scholar
  • 94 Cazanave SC, Mott JL, Elmi NA , et al. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res 2011; 52 (8) 1517-1525
    CrossrefPubMedGoogle Scholar
  • 95 Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res 2012; 347 (1) 245-256
    CrossrefPubMedGoogle Scholar
  • 96 Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134 (6) 1655-1669
    CrossrefPubMedGoogle Scholar
  • 97 Miele L, Beale G, Patman G , et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008; 135 (1) 282-291.e1
    CrossrefPubMedGoogle Scholar
  • 98 Tu X, Zhang H, Zhang J , et al. MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway. J Pathol 2014; 234 (1) 46-59
    CrossrefPubMedGoogle Scholar
  • 99 Lakner AM, Steuerwald NM, Walling TL , et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 2012; 56 (1) 300-310
    CrossrefPubMedGoogle Scholar
  • 100 Guo CJ, Pan Q, Cheng T, Jiang B, Chen GY, Li DG. Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J 2009; 276 (18) 5163-5176
    CrossrefPubMedGoogle Scholar
  • 101 He Y, Huang C, Sun X, Long XR, Lv XW, Li J. MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal 2012; 24 (10) 1923-1930
    CrossrefPubMedGoogle Scholar
  • 102 Maubach G, Lim MC, Chen J, Yang H, Zhuo L. miRNA studies in in vitro and in vivo activated hepatic stellate cells. World J Gastroenterol 2011; 17 (22) 2748-2773
    CrossrefPubMedGoogle Scholar
  • 103 Marquez RT, Bandyopadhyay S, Wendlandt EB , et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010; 90 (12) 1727-1736
    CrossrefPubMedGoogle Scholar
  • 104 Zhang Z, Zha Y, Hu W , et al. The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem 2013; 288 (52) 37082-37093
    CrossrefPubMedGoogle Scholar
  • 105 Wang T, Zhang L, Shi C , et al. TGF-β-induced miR-21 negatively regulates the antiproliferative activity but has no effect on EMT of TGF-β in HaCaT cells. Int J Biochem Cell Biol 2012; 44 (2) 366-376
    CrossrefPubMedGoogle Scholar
  • 106 Dey N, Ghosh-Choudhury N, Kasinath BS, Choudhury GG. TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS ONE 2012; 7 (8) e42316
    CrossrefPubMedGoogle Scholar
  • 107 Li ZJ, Ou-Yang PH, Han XP. Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal 2014; 26 (1) 141-148
    CrossrefPubMedGoogle Scholar
  • 108 Iizuka M, Ogawa T, Enomoto M , et al. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair 2012; 5 (1) 12
    CrossrefPubMedGoogle Scholar
  • 109 Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 2012; 421 (1) 4-8
    CrossrefPubMedGoogle Scholar
  • 110 Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133 (2) 647-658
    CrossrefPubMedGoogle Scholar
  • 111 Takashima M, Parsons CJ, Ikejima K, Watanabe S, White ES, Rippe RA. The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation. J Gastroenterol 2009; 44 (8) 847-855
    CrossrefPubMedGoogle Scholar
  • 112 Thum T, Gross C, Fiedler J , et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456 (7224) 980-984
    CrossrefPubMedGoogle Scholar
  • 113 Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 2009; 583 (4) 759-766
    CrossrefPubMedGoogle Scholar
  • 114 Venugopal SK, Jiang J, Kim TH , et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 2010; 298 (1) G101-G106
    CrossrefPubMedGoogle Scholar
  • 115 Mann J, Chu DC, Maxwell A , et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138 (2) 705-714 , 714.e1–714.e4
    CrossrefPubMedGoogle Scholar
  • 116 Chen C, Wu CQ, Zhang ZQ, Yao DK, Zhu L. Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation. Exp Cell Res 2011; 317 (12) 1714-1725
    CrossrefPubMedGoogle Scholar
  • 117 Guo CJ, Pan Q, Jiang B, Chen GY, Li DG. Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis 2009; 14 (11) 1331-1340
    CrossrefPubMedGoogle Scholar
  • 118 Murakami Y, Toyoda H, Tanaka M , et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE 2011; 6 (1) e16081
    CrossrefPubMedGoogle Scholar
  • 119 Roderburg C, Mollnow T, Bongaerts B , et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS ONE 2012; 7 (3) e32999
    CrossrefPubMedGoogle Scholar
  • 120 Pogribny IP, Starlard-Davenport A, Tryndyak VP , et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010; 90 (10) 1437-1446
    CrossrefPubMedGoogle Scholar
  • 121 Li J, Ghazwani M, Zhang Y , et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013; 58 (3) 522-528
    CrossrefPubMedGoogle Scholar
  • 122 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56 (6) 1384-1391
    CrossrefPubMedGoogle Scholar
  • 123 Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1-20
    PubMedGoogle Scholar
  • 124 Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52 (4) 297-303
    CrossrefPubMedGoogle Scholar
  • 125 Cirera-Salinas D, Pauta M, Allen RM , et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012; 11 (5) 922-933
    CrossrefPubMedGoogle Scholar
  • 126 Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28 (40) 3526-3536
    CrossrefPubMedGoogle Scholar
  • 127 Fujiyoshi M, Ozaki M. Molecular mechanisms of liver regeneration and protection for treatment of liver dysfunction and diseases. J Hepatobiliary Pancreat Sci 2011; 18 (1) 13-22
    CrossrefPubMedGoogle Scholar
  • 128 Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29 (36) 4989-5005
    CrossrefPubMedGoogle Scholar
  • 129 Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ Res 2012; 110 (3) 483-495
    CrossrefPubMedGoogle Scholar
  • 130 Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20 (9) 1487-1495
    CrossrefPubMedGoogle Scholar
  • 131 Yamada H, Suzuki K, Ichino N , et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013; 424: 99-103
    CrossrefPubMedGoogle Scholar
  • 132 Zhang X, Zhang Z, Dai F , et al. Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C. PLoS ONE 2014; 9 (3) e92112
    CrossrefPubMedGoogle Scholar
  • 133 Wang K, Zhang S, Marzolf B , et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009; 106 (11) 4402-4407
    CrossrefPubMedGoogle Scholar
  • 134 Miyaaki H, Ichikawa T, Kamo Y , et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014; 34 (7) e302-e307
    CrossrefPubMedGoogle Scholar
  • 135 Tryndyak VP, Latendresse JR, Montgomery B , et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol 2012; 262 (1) 52-59
    CrossrefPubMedGoogle Scholar
  • 136 Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM ; Acute Liver Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J Med Virol 2014; 86 (9) 1507-1514
    CrossrefPubMedGoogle Scholar
  • 137 Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011; 6 (8) e23937
    CrossrefPubMedGoogle Scholar
  • 138 Chen YP, Jin X, Xiang Z, Chen SH, Li YM. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int 2013; 33 (8) 1257-1265
    CrossrefPubMedGoogle Scholar
  • 139 Bala S, Petrasek J, Mundkur S , et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012; 56 (5) 1946-1957
    CrossrefPubMedGoogle Scholar
  • 140 Ogawa T, Enomoto M, Fujii H , et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012; 61 (11) 1600-1609
    CrossrefPubMedGoogle Scholar
  • 141 Zhang Y, Liu D, Chen X , et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39 (1) 133-144
    CrossrefPubMedGoogle Scholar
  • 142 Ismail N, Wang Y, Dakhlallah D , et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood 2013; 121 (6) 984-995
    CrossrefPubMedGoogle Scholar
  • 143 Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3 (1) 1
    CrossrefPubMedGoogle Scholar
  • 144 Wang X, Yu B, Ren W , et al. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J Control Release 2013; 172 (3) 690-698
    CrossrefPubMedGoogle Scholar
  • 145 Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell 2012; 3 (5) 364-371
    CrossrefPubMedGoogle Scholar
  • 146 Janssen HL, Reesink HW, Lawitz EJ , et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368 (18) 1685-1694
    CrossrefPubMedGoogle Scholar
  • 147 Rayner KJ, Suárez Y, Dávalos A , et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328 (5985): 1570-1573
    CrossrefPubMedGoogle Scholar
  • 148 Sayed D, Rane S, Lypowy J , et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008; 19 (8) 3272-3282
    CrossrefPubMedGoogle Scholar
  • 149 Szabo G, Sarnow P, Bala S. MicroRNA silencing and the development of novel therapies for liver disease. J Hepatol 2012; 57 (2) 462-466
    CrossrefPubMedGoogle Scholar
  • 150 Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci 2008; 97 (1) 225-236
    CrossrefPubMedGoogle Scholar
  • 151 Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19 (1) 92-105
    PubMedGoogle Scholar
  • 152 Choi SE, Fu T, Seok S , et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 2013; 12 (6) 1062-1072
    CrossrefPubMedGoogle Scholar
  • 153 Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol 2013; 58 (4) 785-791
    CrossrefPubMedGoogle Scholar
  • 154 Krutzfeldt J, Rajewsky N, Braich R , et al. Silencing of microRNAs in vivo with “antagomirs”. Nature 2005; 438 (7068) 685-689
    CrossrefPubMedGoogle Scholar
  • 155 Chen YJ, Zhu JM, Wu H , et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PloS ONE 2013; 8 (6) e66577
    CrossrefPubMedGoogle Scholar